- Extensive documents like stakeholder comments from AMP and others, are online here.
- Draft legislative text (basically the DTWG proposal in legislative form), here.
- My own running notes while I watched the hearing (20pp, 7000 words, in the cloud here).
- Coverage at subscription sources Genomeweb (here), Gray Sheet (here), and NYT (here).
For his side, Dr. Shuren discussed problems with the proposed House legislation (to create a new FDA diagnostics center with new rules and standards). He described a University of Texas study where samples from 105 cancer patients were sent to to labs with 50% disagreement in the results. [at 1 hr 9 min]. He was concerned that "enhanced CLIA" proposals would perpetuate and worsen a "bifurcated system." [minute 35]. Today, there is a bifurcated system "where on one side of the street, a test is regulated by FDA, on the other side of the street, by CLIA, and the people being put at risk are patients." [minute 42]. Shuren emphasized multiple times that enhanced CLIA (with clinical validity review on the CLIA side) which only make the "bifurcated system" issue worse, not better.
Patrick Conway, Chief Medical Officer of CMS, discussed CLIA. He repeatedly answered questions by describing CLIA as: monitoring lab protocols, equipment, and staff training, with 25 CMS central employers and 100 field staff, mostly former lab techs, and seven deemed certification bodies. In response to many questions, he stuck closely to repeating those talking points. He stated that FDA has a "critical role" in determining clinical validity. [37 minutes]. "FDA and CMS can work together, FDA assessing premarket clinical validity and CMS enforcing laboratory standards." [41 minutes]. He strongly discouraged suggestions that clinical validity be added to the CLIA system, since the staff and system were not prepared for it.
[*] Before 1988, CLIA governed hospitals serving Medicare patients and interstate labs. CLIA '88 extended its scope to all independent and physician operated labs.